Specialty and infusion are the roles where a US pharmacy search most often stalls, and it is rarely because the salary is wrong. It is because the market is growing several times faster than the number of people who have actually done the work. Here is what makes these roles different, what the four provider models each need, and how to make a hard role fillable.
What this guide covers
- The demand is growing faster than the pool
- Four reasons these roles sit at the hard end
- Why starting from zero costs you the candidate
- Four provider models, four different hires
- Infusion is four different settings, not one
- What we screen for before you see anyone
- How to make a hard role fillable, and where we come in
- Frequently asked questions
The demand is growing faster than the pool
Specialty medicines are a small share of patients and an enormous share of money. Fewer than five per cent of the population uses them, yet they have accounted for at least half of US pharmaceutical spending in recent years, and are expected to pass 55 per cent of total spending in developed markets by 2028. By the middle of 2024, roughly 75 per cent of the 7,000 drugs in development were specialty medicines. Oncology alone is forecast to grow at 14 to 17 per cent a year through 2028.
Infusion is on a similar curve. The US home infusion therapy market was worth 21.52 billion dollars in 2025 and 23.58 billion in 2026, and is projected to reach 49.83 billion by 2034, a compound growth rate of 9.81 per cent. The named drivers are exactly the things that create pharmacy vacancies: the shift of infusion out of hospitals into home and alternate sites, more chronic and complex disease, and the expansion of specialty pharmacy networks and ambulatory infusion centers.
Now put the workforce next to it. The US Bureau of Labor Statistics projects pharmacist employment to grow five per cent between 2025 and 2035, with about 12,500 openings a year across the entire profession, most of them replacing people who move roles or leave. Specialty and infusion are competing for a slice of that, against health systems, PBM-owned pharmacies, hub providers and manufacturers, all at once. Demand is compounding at nine per cent and the workforce is not.
This is a pool problem, not a pay problem. Raising the salary on a specialty role helps you win a candidate away from another employer. It does not create a new person who has run prior authorizations for a limited distribution drug. A pool this thin does not respond to advertising, because the people in it are employed and are not looking for you. It gets worked through relationships that already exist, and that is the actual thing an employer is buying when they hand a specialty search to a specialist. If you are starting to build those relationships on the day the role opens, you are already behind.
Four reasons these roles sit at the hard end
The experience is not as transferable as it looks
A strong retail or hospital pharmacist is not automatically a specialty pharmacist. Limited distribution networks, manufacturer hub relationships, prior authorization workflows and copay assistance are learned on the job in a specialty setting. On paper the licenses match. In practice the working knowledge does not.
Accreditation and USP 797 put a floor under the job
Where the role touches sterile compounding, the November 2023 revision of USP chapter 797 increased the frequency of competency evaluation across all categories, and requires garbing competency before anyone compounds, plus ongoing gloved fingertip sampling and media fill testing. You are not hiring someone who will learn aseptic technique later.
The payer side is its own discipline
Benefits investigation, prior authorization, copay and financial assistance, adherence and refill management. These sit alongside clinical management rather than under it, and the person who is excellent at one is often unremarkable at the other. Briefs that ask for both at a single salary tend to stay open.
Everyone is hiring from the same pool
Clinical pharmacist postings rose about five per cent year on year and ambulatory care roles nearly eight per cent. Specialty, oncology and infectious diseases are named as rising demand areas. When the same few hundred qualified people in a region are being approached by four employers, response rates fall and counter-offers rise.
Why starting from zero costs you the candidate
Healthcare hiring averages 56 days to fill a role, and specialized hospital roles can run to 250 days. In specialty and infusion those numbers get worse rather than better, because the qualifying pool is smaller and the same few hundred people in a region are being approached by several employers at once.
That turns hiring into a queue. The employer who has already spoken to the right person, knows what they earn, knows which states they are licensed in and knows what would actually move them, is at the front of it. The employer opening a requisition and writing an advert is at the back, and by the time they have built that picture from scratch the candidate has an offer somewhere else.
This is the whole speed argument in one line. We are not faster because we work harder than your team does. We are faster because on a specialty role most of the sourcing and screening has already happened before you brief us. On a rare role that is not a marginal gain. It is the difference between a shortlist in days and a search that quietly runs for months.
It cuts the other way too, and we would rather say so up front. If we do not already know your corner of the market, we will tell you that at the briefing rather than let you assume a head start we do not have. More than half of candidates lose patience waiting after an interview, so the worst outcome for you is a search that looks active for six weeks and then starts again.
Four provider models, four different hires
The single most common reason a specialty brief goes wrong is treating specialty as one market. It is four, and they want different people. Our specialty pharmacy recruitment page is built around this split.
| Provider model | What the role actually is | What to screen hardest |
|---|---|---|
| Health system specialty | Embedded in the health system, close to the prescribing clinic, often integrated with ambulatory care. | Clinical depth and comfort working alongside physicians |
| Independent and regional | Smaller team, wider remit. The same person may touch referral, benefits and clinical management. | Breadth, and willingness to work outside a narrow lane |
| PBM-owned specialty | High volume, defined processes, strong metrics culture. | Throughput, accuracy and tolerance for process |
| Hub services and patient support | Manufacturer-facing. Access, reimbursement and adherence rather than dispensing. | Payer knowledge and communication skills over dispensing volume |
Accreditation matters across all four. If your organization is URAC or ACHC accredited, or working toward it, say so in the brief. Candidates who have been through an accreditation cycle are a materially different proposition to candidates who have not.
Infusion is four different settings, not one
Infusion hiring splits the same way, which is how our specialty infusion recruitment work is organized:
- Specialty infusion pharmacies, where compounding capability and payer knowledge have to coexist in the same team
- Home infusion providers, where the job includes coordinating care that happens somewhere nobody from the pharmacy can see
- Ambulatory infusion centers, where scheduling, chair utilization and nurse coordination sit alongside the clinical work
- Health system infusion, where the role is closer to hospital pharmacy and the internal politics of a large provider
If the role involves preparing the therapy rather than only managing it, you are also hiring into a compounding pharmacy skill set, and the competency requirements above apply.
What we screen for before you see anyone
On a specialty or infusion brief, the screening is the value. Sending five clinically strong pharmacists who have never touched a prior authorization is not a shortlist, it is a delay.
- Which provider model they have actually worked in, not just the job title they held
- Whether their experience is clinical, payer-side, or genuinely both, stated plainly rather than implied
- Therapy areas handled, because oncology, immunology and rare disease are not interchangeable
- Sterile compounding currency, including whether their competency assessments are up to date
- Accreditation exposure, and whether they have been through a survey
- State licensure and a realistic start date, checked before interview rather than at offer. Our guide to license reciprocity explains why this is the check that most often saves a timeline
How to make a hard role fillable, and where we come in
Five things that reliably move a stalled specialty or infusion search.
- Pick a side and say so. Decide whether the priority is clinical depth or payer-side depth, and write the brief for that. A role that asks for equal excellence in both, at one salary, is a role that stays open. This is the first conversation we have on a specialty brief and it is usually the one that unblocks it. If you are not sure which you need, describe the team you already have and we will tell you which gap is actually costing you.
- Be honest about the compounding requirement. If the person will be compounding, say it in the first line. Candidates who do not want to be in a cleanroom will withdraw at interview, which costs you two weeks. We ask this before we source anyone, and we screen for current competency assessments rather than a line on a CV, so nobody drops out over something that was knowable in week one.
- Pay at the specialty band. Senior and manager level pharmacy roles were running at 150,000 to 185,000 dollars and above in 2026. A specialty role priced at a generalist band signals that you do not know what you are buying. We will tell you where your number sits against that state and that provider model before the search starts, including when the honest answer is that the role is not fillable at it.
- Shorten the process. In a market where four employers are chasing the same person, a two stage process that closes in three weeks beats a three stage one that closes in eight. The part you cannot easily do from inside a busy pharmacy is the chasing: coordinating the diary, briefing both sides and getting feedback back inside 48 hours. That is the unglamorous half of the job and the half that decides whether you get an acceptance. We wrote about where the weeks actually go in how a pharmacy recruitment agency fills a role.
- Consider an out of state candidate deliberately. Widening the geography is often the only way to widen the pool for a rare role. We establish which states a candidate is licensed in and what a transfer would take before you interview them, so widening the geography does not quietly widen your timeline instead.
If you are building a specialty or infusion function rather than filling one seat, that is a mapped search rather than a contingent one, and it is worth talking about how it is structured. The options sit on our for employers hub, and the wider US picture is on the US specialisms hub.
Frequently asked questions
Why do specialty pharmacy roles take longer to fill than retail?
Because the qualifying pool is much smaller. A retail role can draw on most licensed pharmacists in a region. A specialty role needs someone who has worked in a specialty setting and understands limited distribution, prior authorization and copay assistance, which is learned on the job. Add sterile compounding currency and the pool narrows again.
Can a hospital pharmacist move into specialty or infusion?
Often yes, and it is one of the more realistic routes, particularly into health system specialty or health system infusion where the setting is familiar. The honest caveat is the payer side. A hospital pharmacist moving into a hub or a PBM-owned specialty pharmacy is learning a new discipline, and the onboarding needs to reflect that rather than assume it.
What is the hardest specialty pharmacy role to fill?
In our experience, roles that require clinical depth and payer-side depth in the same person, in a market with one or two other specialty employers, and with a sterile compounding requirement on top. Any one of those is manageable. All three together is a mapped search, not an advert.
Does USP 797 affect who we can hire?
It affects what you have to be able to demonstrate about them. The November 2023 revision increased competency evaluation frequency across all categories and requires garbing competency before anyone prepares a compounded sterile preparation, with ongoing gloved fingertip sampling and media fill testing. In hiring terms it means sterile compounding currency is a screening question, not something to sort out after the start date.
Do you recruit infusion nurses and technicians as well as pharmacists?
We recruit pharmacy technicians into specialty and infusion teams, including technicians with sterile compounding experience, who are frequently the constraint on an infusion operation rather than the pharmacists. Tell us the full team shape and we will tell you which parts we can cover.
We are opening an ambulatory infusion center. When should we start hiring?
Earlier than feels necessary, and pharmacist first. The same sequencing logic applies as in our retail pharmacy opening timeline: the licensed hire gates the permit, the permit gates everything else, and a specialty pool is thinner than a retail one so the search takes longer from the start.
Hiring in specialty or infusion?
Tell us the provider model, the state and whether the priority is clinical or payer-side. We will tell you honestly how hard it will be and what would make it easier.
Talk to our US teamSpecialty pharmacy recruitmentSources and further reading US Bureau of Labor Statistics Occupational Outlook Handbook, Pharmacists, 2025 data with projections to 2035. CarelonRx, specialty drug growth. Fortune Business Insights, US home infusion therapy market, 2025 to 2034. Research.com, 2026 pharmacy job market report. Hardy Diagnostics and USP, chapter 797 revisions effective November 2023. Market projections are third party forecasts, not Quad Recruitment data.